NCT06446570View on ClinicalTrials.gov

Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 10, 2017

Primary Completion Date

February 22, 2019

Study Completion Date

June 3, 2021

Conditions
HNSCCHead and Neck Neoplasms
Interventions
DRUG

Durvalumab,Tremelimumab

Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

All Listed Sponsors
collaborator

Korean Cancer Study Group

OTHER

lead

Seoul National University Hospital

OTHER

NCT06446570 - Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma | Biotech Hunter | Biotech Hunter